Why Microsleeps May Redefine ‘Quality of Wake’ in Narcolepsy Type 1
Phase 3 data on the orexin agonist oveporexton suggests that reducing microsleep frequency offers a more accurate reflection of real-world treatment response than traditional wakefulness tests alone.